Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Broxmeyer, H. E. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J. Exp. Med. 210, 205–208 (2013).
2. Cody, J. D. & Hodson, E. M. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database Syst. Rev. 1, CD003266 (2016).
3. Glaspy, J. Current status of use of erythropoietic agents in cancer patients. Semin. Thromb. Hemost. 40, 306–312 (2014).
4. Hua, S. et al. Technologies for glycomic characterization of biopharmaceutical erythropoietins. Trends Anal. Chem. 68, 18–27 (2015).
5. Koury, M. J. Sugar coating extends half-lives and improves effectiveness of cytokine hormones. Trends Biotechnol. 21, 462–464 (2003).